Considering these previous evidences, in this work we have delved into TERCELOI, exploring the circulating expression levels and functional activity (bioactivity), of TGF-β superfamily in OI patients before and after being subjected to the cell therapy (Infante et al., 2021). Here, TGFB1 is linked to osteogenesis imperfecta.